Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility

Journal of Psychiatric Research

Volumn 96, Issue , 2018, Pages 100-107

  Bradley, Paul ^a,h   Shiekh, Michael ^b   Mehra, Vishaal ^c   Vrbicky, Keith ^d,e,f   Layle, Stacey ^c   Olson, Marilyn C ^g   Maciel, Alejandra ^g   Cullors, Ali ^g   Garces, Jorge A ^g   Lukowiak, Andrew A ^g  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Relaro Medical Trials   (United States)

^c Artemis Institute for Clinical Research   (United States)

^d Midwest Health Partners   (United States)

^e CREIGHTON UNIVERSITY   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g AltheaDx   (United States)

^h Meridian Clinical Research   (United States)

Author keywords

Anxiety; Depression; Efficacy; Pharmacogenetics; Precision medicine; Treatment response

Indexed keywords

ADULT; AGED; ANXIETY DISORDER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON DEPRESSION RATING SCALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; STUDY DESIGN; TREATMENT OUTCOME; CLINICAL DECISION MAKING; CLINICAL TRIAL; FOLLOW UP; GENETICS; MIDDLE AGED; PERSONALIZED MEDICINE; PHARMACOGENETIC VARIANT; PSYCHOLOGICAL RATING SCALE; TIME FACTOR;

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CLINICAL DECISION-MAKING; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHARMACOGENOMIC VARIANTS; PRECISION MEDICINE; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85030720945     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2017.09.024     Document Type: Article

References (38)

1. Altar, C.A., Hornberger, J., Shewade, A., Cruz, V., Garrison, J., Mrazek, D., Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int. Rev. Psychiatry 25 (2013), 509–533.
2. Anxiety and Depression Association of America, Facts and Statistics. Updated August, 2016 https://www.adaa.org (Accessed on 8 February, 2017).
3. Barbui, C., Cipriani, A., Patel, V., Ayuso-Mateos, J.L., van Ommeren, M., Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br. J. Psychiatry 198:1 (2011), 11–16.
4. Bystritsky, A., Treatment-resistant anxiety disorders. Mol. Psychiatry 11 (2006), 805–814.
5. Caudle, K.E., Klein, T.E., Hoffman, J.M., Muller, D.J., Whirl-Carillo, M., Gong, L., et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr. Drug Metab. 15 (2014), 209–217.
6. Cusin, C., Yang, H., Yeung, A., Fava, M., Rating scales for depression. Baer, L., Blais, M.A., (eds.) Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health, 2010, Humana Press a Part of Springer Science, New York, NY, 7–35.
7. Evans, W.E., Johnson, J.A., Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2 (2001), 9–39.
8. Evans, W.E., Relling, M.V., Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286 (1999), 487–491.
9. Fava, M., Rush, A.J., Alpert, J.E., Balasubramani, G.K., Wisniewski, S.R., Carmin, C.N., et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am. J. Psychiatry 165 (2008), 342–351.
10. Gelenberg, A.J., Freeman, M.P., Markowitz, J.C., Rosenbaum, J.F., Thase, M.E., Trivedi, M.H., Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Oct. 2010, American Psychiatric Association Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf (Accessed on 10 February 2017).
11. Goodman, W.K., Selecting pharmacotherapy for generalized anxiety disorder. J. Clin. Psychiatry 65:13 Suppl. l (2004), 8–13.
12. Greenberg, P.E., Fournier, A.A., Sisitsky, T., Pike, C.T., Kessler, R.C., The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J. Clin. Psychiatry 76 (2015), 155–162.
13. Hall-Flavin, D.K., Winner, J.G., Allen, J.D., Jordan, J.J., Nesheim, R.S., Snyder, K.A., et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl. Psychiatry, 2, 2012, e172, 10.1038/tp.2012.99.
14. Hall-Flavin, D.K., Winner, J.G., Allen, J.D., Carhart, J.M., Proctor, B., Snyder, K.A., et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 23 (2013), 535–548.
15. Hamilton, M., The assessment of anxiety states by rating. Br. J. Med. Psychol. 32 (1959), 50–55.
16. Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960), 56–62.
17. Helfand, M., Peterson, K., Dieperink, E., Ferguson, L., Anderson, J., Evidence Brief: the Comparative Effectiveness, Harms and Cost-effectiveness of Pharmacogenomics-guided Antidepressant Treatment versus Usual Care for Major Depressive Disorder. May 2016, Evidence-based Synthesis Program Coordinating Center, Portland CA Health Care System.
18. Hicks, J.K., Bishop, J.R., Sangkuhi, K., Muller, D.J., Ji, Y., Leckband, S.G., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98 (2015), 127–134.
19. Huynh, N.N., McIntyre, R.S., What are the implications of the STAR*D Trial for primary care? A review and synthesis. Prim. Care Companion J. Clin. Psychiatry 10 (2008), 91–96.
20. Kessler, R.C., Berglund, P., Demler, O., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 (2005), 593–602.
21. Kessler, R.C., Birnbaum, H., Shahly, V., Bromet, E., Hwang, I., McLaughlin, K.A., Age differences in the prevalence and comorbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative. April Depress Anxiety 27:4 (2010), 351–364, 10.1002/da.20634.
22. Lesch, K.-P., Bengel, D., Heils, A., Sabol, S.Z., Greenberg, B.D., Petri, S., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996), 1527–1531.
23. Mark, T.L., Levit, K.R., Buck, J.A., Psychotropic drug prescriptions by medical specialty. Psychiatr. ServSept, 60(9), 2009, 1667, 10.1176/ps_2009.60.9.1167.
24. Mrazek, D.A., Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin. Neurosci. 12 (2010), 69–76.
25. Porcelli, S., Drago, A., Fabbri, C., Gibiino, S., Calati, R., Serretti, A., Pharmacogenetics of antidepressant response. J. Psychiatry Neurosci. 36 (2011), 87–113, 10.1503/jpn.100059.
26. Pratt, L.A., Brody, D.J., Depression in the U.S. household population, 2009-2012. NCHS Data Brief. 172 (2014 Dec), 1–8.
27. Pratt, V.M., Zehnbauer, B., Wilson, J.A., Baak, R., Babic, N., Bettinotti, M., et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. J. Mol. Diagn 12 (2010), 835–846.
28. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Nov Am. J. Psychiatry 163 (2006), 1905–1917.
29. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59:20 Suppl. l (1998), 22–33.
30. Singh, A.B., Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin. Psychopharmacol. Neurosci. 13:2 (2015), 150–156 [PMC free article] [PubMed] [Reference list].
31. Siu, A.L., U.S. Preventative services Task Force, Screening for depression in adults US preventative services Task Force recommendation statement. JAMA 315 (2016), 380–387.
32. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D implications for clinical practice. Am. J. Psychiatry 163 (2006), 28–40.
33. U.S Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States, With Special Feature on Prescription Drugs. 2013 Available at: https://www.cdc.gov/nchs/data/hus/hus13.pdf (Accessed on 10, February 2017).
34. U.S Food and Drug Administration. Table of pharmacogenomics biomarkers in drug labeling. www.fda.gov. Updated 7 November, 2016. (Accessed on 10 February, 2017).
35. U.S. Food and Drug Administration, CDER, CBER, CDRH, Guidance for Industry, Clinical Pharmacogenomics: Premarket Evaluation in Early-phase Clinical Studies and Recommendations for Labeling. January 2013.
36. Whirl-Carrillo, M., McDonagh, E.M., Hebert, J.M., Gong, L., Sangkuhl, K., Thorn, C.F., Altman, R.B., Klein, T.E., Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92:4 (2012), 414–417 https://www.pharmgkb.org/page/pgxGeneRef.
37. Winner, J.G., Carhart, J.M., Altar, C.A., Allen, J.D., Dechairo, B.M., et al. A Prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov. Med. 16 (2013), 219–227.
38. Wittchen, H.U., Kessler, R.C., Beesdo, K., Krause, P., Hofler, M., Hoyer, J., Generalized anxiety and depression in primary care: prevalence, recognition, and management. J. Clin. Psychiatry 63 (2002), 24–34.